Affinage

ZC3H13

Zinc finger CCCH domain-containing protein 13 · UniProt Q5T200

Length
1668 aa
Mass
196.6 kDa
Annotated
2026-06-11
44 papers in source corpus 22 papers cited in narrative 22 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ZC3H13 is a CCCH zinc-finger protein that serves as a core scaffolding subunit of the nuclear N6-methyladenosine (m6A) methyltransferase "writer" complex, where it anchors the assembly in the nucleus and thereby licenses METTL3-dependent m6A deposition on mRNA (PMID:29547716, PMID:29555755). It performs this role architecturally: ZC3H13 (and its Drosophila ortholog Xio/Flacc) physically interacts with all known writer subunits and bridges the WTAP homolog Fl(2)d to the mRNA-binding factor Nito/RBM15, physically coupling the RNA-recruiting module to the catalytic core (PMID:29535189, PMID:29555755). Loss of ZC3H13 causes WTAP, Virilizer, and Hakai to mislocalize from nucleus to cytoplasm, globally reducing mRNA m6A and impairing functions including mouse embryonic stem cell self-renewal and Drosophila sex determination (PMID:29547716, PMID:29555755). Through this writer activity ZC3H13 controls the fate of specific transcripts in a reader-dependent manner, with outcomes determined by which reader engages the modified mRNA: YTHDF2 and YTHDC1 mediate destabilization of targets such as IQGAP1, PRDX6, and Bax (PMID:36739231, PMID:40646387, PMID:39307407), YTHDF1 promotes translation or post-transcriptional activation of targets including PHF10 and SNTB1 (PMID:35033590, PMID:40774945), and IGF2BP proteins stabilize transcripts such as NABP1 and SLC3A2 (PMID:39985591, PMID:42217127). These target-level effects govern mRNA stability, translation, DNA damage repair, glycolytic reprogramming, ferroptosis, and immune-cell phenotypes across diverse cancer and tissue-injury contexts (PMID:35033590, PMID:35003256, PMID:40646387, PMID:42163390). Beyond its scaffolding role in the writer complex and the catalog of individual target transcripts, no further intrinsic enzymatic activity for ZC3H13 itself is characterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2018 High

    Established that ZC3H13 is not merely associated with the m6A machinery but is structurally required to keep the writer complex in the nucleus, defining its core function as a localization scaffold.

    Evidence siRNA knockdown with subcellular fractionation, immunofluorescence, and m6A quantification in mouse embryonic stem cells

    PMID:29547716

    Open questions at the time
    • Does not resolve the structural basis or domain of ZC3H13 that mediates nuclear anchoring
    • Does not define how m6A loss mechanistically links to the self-renewal defect
  2. 2018 High

    Defined the molecular bridging logic of ZC3H13 — connecting the mRNA-binding subunit RBM15/Nito to the WTAP/Fl(2)d core — explaining how the writer is recruited to its RNA substrates.

    Evidence Co-IP, mass spectrometry interactome, and genetic epistasis in Drosophila sex determination with m6A quantification, conserved in mouse

    PMID:29535189

    Open questions at the time
    • Does not map the precise interaction interfaces
    • Does not establish whether bridging is constitutive or regulated
  3. 2018 High

    Confirmed ZC3H13/Xio as a bona fide writer-complex member interacting with all five known subunits, with loss-of-function phenocopying other m6A factors.

    Evidence Co-IP, immunofluorescence colocalization, Sxl splicing and sex-determination assays, and m6A quantification in Drosophila

    PMID:29555755

    Open questions at the time
    • Does not establish stoichiometry within the complex
    • Does not separate scaffolding from any catalytic contribution
  4. 2018 Medium

    Began connecting ZC3H13 loss to oncogenic signaling, positioning it as an upstream suppressor of the Ras-ERK pathway in colorectal cancer.

    Evidence siRNA knockdown/overexpression with Western blotting of pathway components and proliferation/invasion assays

    PMID:30311220

    Open questions at the time
    • No direct biochemical link between ZC3H13 and Ras-ERK components
    • Does not identify the m6A target transcripts mediating the effect
  5. 2021 Medium

    Demonstrated that ZC3H13-dependent m6A controls metabolic reprogramming by destabilizing PKM2 mRNA, linking the writer scaffold to glycolysis in hepatocellular carcinoma.

    Evidence MeRIP-qPCR, RIP, actinomycin D stability assay, luciferase reporter, and rescue in HCC cells

    PMID:35003256

    Open questions at the time
    • Reader protein mediating PKM2 destabilization not identified
    • Single lab, no in vivo validation reported
  6. 2022 Medium

    Showed ZC3H13 m6A can promote (not only repress) target output, driving YTHDF1-dependent translation of PHF10 to sustain homologous recombination repair.

    Evidence MeRIP-qPCR, knockdown, m6A quantification, DNA-damage foci assays, and YTHDF1-rescue experiments

    PMID:35033590

    Open questions at the time
    • Does not explain how reader choice (translation vs decay) is determined for ZC3H13 targets
    • Single lab
  7. 2023 Medium

    Distinguished a YTHDF2-mediated decay branch of ZC3H13 function by showing destabilization of IQGAP1 mRNA, with reader knockdown reversing the effect.

    Evidence MeRIP-qPCR, RIP, stability assay, YTHDF2 knockdown rescue, and xenograft in papillary thyroid carcinoma

    PMID:36739231

    Open questions at the time
    • Does not address why some ZC3H13 targets use YTHDF2 vs YTHDF1/IGF2BP readers
    • Single lab
  8. 2024 Medium

    Extended the reader repertoire to YTHDC1, showing ZC3H13 m6A destabilizes Bax mRNA via YTHDC1 to limit lung epithelial apoptosis.

    Evidence MeRIP-qPCR, RNA-binding assay, stability assay, reader identification, and in vivo BLM model

    PMID:39307407

    Open questions at the time
    • Does not clarify determinants of YTHDC1 versus cytoplasmic reader engagement
    • Single lab
  9. 2025 Medium

    Established IGF2BP-dependent stabilization as another ZC3H13 output, linking the writer to cell-cycle arrest, osteogenesis, and ferroptosis through targets such as NABP1 and SLC3A2.

    Evidence MeRIP, RIP, stability assays with IGF2BP1/IGF2BP2 dependence, ChIP/luciferase for upstream FOXO3, and in vivo models

    PMID:39985591 PMID:42217127

    Open questions at the time
    • Reader-selection rules across IGF2BP1 vs IGF2BP2 not defined
    • Upstream transcriptional control (FOXO3) shown in only one context
  10. 2025 Medium

    Broadened ZC3H13 m6A regulation to non-coding RNA and immune remodeling, including destabilization of KCNQ1OT1 lncRNA and stabilization of UNC5CL to reshape tumor immunity.

    Evidence MeRIP, RIP, RNA pull-down, ChIP, YTHDF2-RIP, m6A-seq/RNA-seq, flow cytometry, and allograft/xenograft models

    PMID:40000487 PMID:41847860 PMID:42163390

    Open questions at the time
    • lncRNA targeting mechanism by the writer not biochemically reconstituted
    • Immune-microenvironment effects are downstream and indirect
  11. 2025 Medium

    Showed that ZC3H13 loss alters writer-complex activity and target specificity to favor pro-metastatic transcripts, and that this dependency is pharmacologically targetable.

    Evidence m6A sequencing, migration/invasion assays, patient co-deletion genomics, and FDA-approved demethylase inhibitor treatment in prostate cancer

    PMID:41105668

    Open questions at the time
    • Mechanism by which ZC3H13 loss shifts target specificity not resolved
    • Single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved what governs the divergent reader outcomes (YTHDF1/YTHDC1/YTHDF2/IGF2BP) and target specificity downstream of ZC3H13-dependent m6A, and whether ZC3H13 contributes anything beyond nuclear scaffolding/bridging.
  • No unifying model for reader selection across ZC3H13 targets
  • No structural model of ZC3H13 within the writer complex
  • Intrinsic biochemical activity of ZC3H13 (if any) undefined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 3 GO:0140096 catalytic activity, acting on a protein 3 GO:0003723 RNA binding 1
Localization
GO:0005634 nucleus 2 GO:0005654 nucleoplasm 2
Pathway
R-HSA-8953854 Metabolism of RNA 3 R-HSA-74160 Gene expression (Transcription) 1
Partners
CBLL1METTL14METTL3RBM15VIRMAWTAP
Complex memberships
m6A methyltransferase (writer) complex

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2018 ZC3H13 is required for nuclear localization of the WTAP-Virilizer-Hakai complex; knockdown of Zc3h13 in mouse embryonic stem cells causes WTAP, Virilizer, and Hakai to translocate from nucleus to cytoplasm, leading to decreased global m6A levels on mRNA and impaired mESC self-renewal. siRNA knockdown, subcellular fractionation, immunofluorescence, m6A dot blot/quantification in mESCs Molecular cell High 29547716
2018 Zc3h13/Flacc promotes m6A deposition by bridging the WTAP homolog Fl(2)d to the mRNA-binding factor Nito/Rbm15, physically connecting the mRNA-binding subunit to the catalytic m6A writer complex in both Drosophila and mice. Co-immunoprecipitation, mass spectrometry interactome, genetic epistasis in Drosophila sex determination, m6A quantification upon Flacc loss Genes & development High 29535189
2018 Drosophila Xio (ortholog of ZC3H13) colocalizes and physically interacts with all five known m6A writer complex subunits (METTL3, METTL14, Fl(2)d/WTAP, Vir/KIAA1429, Nito/Rbm15) in the nucleus; loss of xio phenocopies loss of other m6A factors (sex transformation, Sxl splicing defect, reduced m6A) and encodes a member of the m6A methyltransferase complex. Co-immunoprecipitation, immunofluorescence colocalization, genetic loss-of-function (Sxl splicing assay, sex determination phenotypes), m6A quantification Proceedings of the National Academy of Sciences of the United States of America High 29555755
2018 ZC3H13 loss in colorectal cancer cells activates Ras-ERK signaling and increases expression of Snail, Cyclin D1, and Cyclin E1 while decreasing Occludin and ZO-1, placing ZC3H13 as an upstream suppressor of the Ras-ERK pathway. siRNA knockdown and overexpression, Western blot for pathway components, proliferation and invasion assays Journal of cellular physiology Medium 30311220
2022 ZC3H13-mediated m6A modification of PHF10 mRNA promotes its translation in a YTHDF1-dependent manner; ZC3H13 knockdown downregulates PHF10 m6A methylation and reduces PHF10 protein, impairing homologous recombination repair of DNA double-strand breaks. MeRIP-qPCR, siRNA knockdown, m6A quantification, γH2AX/RAD51/53BP1 foci assay, YTHDF1-rescue experiments Cancer letters Medium 35033590
2021 ZC3H13-induced m6A modification abolishes PKM2 mRNA stability, thereby reducing PKM2 expression and reprogramming glycolysis in hepatocellular carcinoma cells; rescue of PKM2 reverses the suppressive effect of ZC3H13 on HCC cell glycolysis and malignancy. MeRIP-qPCR, RNA immunoprecipitation, mRNA stability assay (actinomycin D), luciferase reporter, rescue experiments Journal of oncology Medium 35003256
2023 ZC3H13 promotes m6A modification of IQGAP1 mRNA, leading to YTHDF2-mediated destabilization and degradation of IQGAP1 mRNA; YTHDF2 knockdown reverses the effect of ZC3H13 overexpression on IQGAP1 mRNA stability, suppressing papillary thyroid carcinoma growth. MeRIP-qPCR, RIP, actinomycin D mRNA stability assay, YTHDF2 knockdown rescue, xenograft model Journal of the Formosan Medical Association Medium 36739231
2025 ZC3H13 promotes m6A modification of NABP1 mRNA, stabilizing it in an IGF2BP1-dependent manner; ZC3H13 knockdown reduces NABP1, alleviating G2/M cell cycle arrest and apoptosis in cisplatin-induced acute kidney injury. MeRIP, ZC3H13 knockdown/overexpression, IGF2BP1-dependent mRNA stability assay, AAV9-mediated silencing in vivo Cellular and molecular life sciences Medium 39985591
2025 ZC3H13 promotes m6A methylation of PRDX6 mRNA, facilitating its degradation in a YTHDF2-dependent manner, reducing PRDX6 expression; reduced PRDX6 activates p53 and suppresses SLC7A11, thereby promoting ferroptosis in alveolar macrophages and contributing to sepsis-associated acute lung injury. MeRIP, YTHDF2-dependent mRNA stability assay, ZC3H13 knockdown/PRDX6 overexpression rescue, lentiviral knockdown in vivo (CLP model) Functional & integrative genomics Medium 40646387
2025 ZC3H13 mediates m6A modification of KCNQ1OT1 lncRNA, reducing its stability in a YTHDF2-dependent manner; loss of KCNQ1OT1 prevents MLL4 recruitment to the TRABD promoter (reducing H3K4me1/2/3 enrichment), thereby decreasing TRABD expression and promoting ferroptosis, which sensitizes doxorubicin-resistant TNBC cells. RIP, RNA pull-down, MeRIP, YTHDF2-RIP, ChIP for H3K4me1/2/3 and MLL4, xenograft model Cell biology and toxicology Medium 40000487
2024 ZC3H13 enhances m6A modification and mRNA stability of ITGA6 in bronchial epithelial cells, promoting ITGA6 expression; ZC3H13/ITGA6 axis drives inflammation, apoptosis, and EMT in COPD models. MeRIP-PCR, actinomycin D mRNA stability assay, ZC3H13 knockdown in cellular and mouse COPD models Cellular signalling Medium 38670474
2024 ZC3H13 promotes m6A modification of Bax mRNA, reducing its stability through the m6A reader YTHDC1, thereby inhibiting Bax expression and lung epithelial cell apoptosis; YTHDC1 was identified as the specific reader mediating this destabilization. MeRIP-qPCR, RNA binding assay (ZC3H13 binds Bax mRNA), actinomycin D stability assay, YTHDC1 identification, ZC3H13 overexpression in BLM-induced mouse and cellular models Experimental cell research Medium 39307407
2023 ZC3H13 promotes m6A modification of HIPK2 mRNA, increasing its stability (reduced degradation rate); this elevates HIPK2 expression and promotes keloid fibroblast proliferation and migration. MeRIP-qPCR, mRNA stability assay (actinomycin D), ZC3H13 knockdown/overexpression in human keloid fibroblasts Biochemical genetics Low 37752292
2023 ZC3H13 promotes m6A modification of DUOX1 mRNA, repressing DUOX1 expression and thereby reducing DUOX1-mediated ferroptosis in laryngeal squamous cell carcinoma cells; CHIP confirmed interaction between DUOX1 and ZC3H13. MeRIP, chromatin immunoprecipitation (ChIP), siRNA knockdown/overexpression, ROS and Fe2+ measurement Tissue & cell Low 37536262
2026 ZC3H13 loss changes m6A writer complex activity and target specificity, decreasing m6A methylation and increasing stability of transcripts that promote migration and invasion; co-loss of ZC3H13 with RB1 and BRCA2 occurs in metastatic prostate cancer; FDA-approved m6A demethylase inhibitors reduce metastatic capabilities of ZC3H13-deficient cells. In vitro and in vivo functional assays for migration/invasion, m6A sequencing, pharmacological inhibition with FDA-approved demethylase inhibitors, patient genomic data co-deletion analysis Cancer research Medium 41105668
2025 ZC3H13 mediates m6A modification of UNC5CL mRNA, stabilizing UNC5CL transcripts via YTHDC1; elevated UNC5CL suppresses the NF-κB–CSF2 signaling axis, thereby inhibiting CSF2-driven recruitment of myeloid-derived suppressor cells and remodeling the immunosuppressive tumor microenvironment in renal cell carcinoma. m6A sequencing combined with RNA-seq, loss/gain-of-function studies, flow cytometry of tumor-infiltrating immune cells, allograft tumor model Journal of experimental & clinical cancer research Medium 42163390
2025 ZC3H13 mediates m6A modification and stability of SLC3A2 mRNA in an IGF2BP2-dependent manner; ZC3H13 silencing suppresses BMSC proliferation and osteogenic differentiation while enhancing ferroptosis through SLC3A2 reduction; FOXO3 acts as a transcriptional activator of ZC3H13, placing ZC3H13 downstream of FOXO3 in a FOXO3/ZC3H13/SLC3A2 cascade. RIP, MeRIP, mRNA stability assay, ChIP and luciferase (FOXO3→ZC3H13 promoter), osteogenic differentiation assays (ALP, Alizarin Red), ROS/Fe2+/MDA measurement Journal of bioenergetics and biomembranes Medium 42217127
2025 ZC3H13 silencing in LPS-stimulated macrophages stabilizes Spic mRNA in an m6A-dependent manner; stabilized Spic inhibits NF-κB pathway activation and promotes macrophage polarization from pro-inflammatory M1 to anti-inflammatory phenotype, alleviating LPS-induced liver injury. Zc3h13 siRNA knockdown in macrophages and C57BL/6 in vivo model, m6A quantification, Spic co-silencing rescue, NF-κB pathway assay Journal of immunology Medium 41847860
2025 ZC3H13 mediates YTHDF1-dependent m6A modification of SNTB1 mRNA, leading to post-transcriptional activation (increased SNTB1 expression), which promotes EMT and metastatic progression in gastric cancer. MeRIP-seq, RNA-seq, Co-immunoprecipitation, YTHDF1-rescue experiments, in vivo and in vitro functional assays Cell death & disease Medium 40774945
2029 ZC3H13 mutation causes abnormal nuclear-to-cytoplasmic metastasis of METTL14 and METTL3 in esophageal squamous cell carcinoma, consistent with its nuclear anchoring role for the m6A writer complex; ZC3H13 promotes m6A modification of CXCL8 mRNA, enhancing its stability and leading to M2 macrophage polarization via the CXCL8–CXCR2 axis. ZC3H13 silencing in CDX model, m6A colorimetric assay, METTL3/METTL14 localization assay, CXCL8/CCL5 qRT-PCR and ELISA, CXCR2 inhibitor rescue Frontiers in immunology Low 40959082
2024 ZC3H13 promotes m6A modification of PJA2 mRNA, stabilizing it; elevated PJA2 ubiquitinates and degrades KSR1, thereby inducing autophagy and suppressing bladder cancer progression. MeRIP for PJA2 m6A, mRNA stability assay, PJA2/KSR1 knockdown/overexpression rescue, in vitro and in vivo functional assays Human cell Low 39614918
2025 ZC3H13-mediated m6A modification of NSUN4 mRNA represses NSUN4 expression; conversely, ZC3H13 knockdown increases NSUN4 m6A but reduces NSUN4 levels, and NSUN4 knockdown promotes chondrocyte mitochondrial dysfunction and pyroptosis, revealing that ZC3H13 modulates chondrocyte fate via m6A regulation of NSUN4. ZC3H13 siRNA knockdown, m6A level quantification of NSUN4, RNA sequencing, NSUN4 knockdown functional assays Cartilage Low 40433805

Source papers

Stage 0 corpus · 44 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Zc3h13 Regulates Nuclear RNA m6A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Molecular cell 768 29547716
2018 Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m6A machinery component Wtap/Fl(2)d. Genes & development 514 29535189
2018 ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. Journal of cellular physiology 112 30311220
2020 Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer. Frontiers in oncology 100 33363011
2022 N6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Military Medical Research 92 35418160
2018 Xio is a component of the Drosophila sex determination pathway and RNA N6-methyladenosine methyltransferase complex. Proceedings of the National Academy of Sciences of the United States of America 84 29555755
2022 ZC3H13-mediated N6-methyladenosine modification of PHF10 is impaired by fisetin which inhibits the DNA damage response in pancreatic cancer. Cancer letters 45 35033590
2012 The Trypanosoma brucei CCCH zinc finger proteins ZC3H12 and ZC3H13. Molecular and biochemical parasitology 32 22366391
2021 ZC3H13 Inhibits the Progression of Hepatocellular Carcinoma through m6A-PKM2-Mediated Glycolysis and Enhances Chemosensitivity. Journal of oncology 29 35003256
2023 Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation. Journal of the Formosan Medical Association = Taiwan yi zhi 22 36739231
2021 N6-Methyladenosine Writer Gene ZC3H13 Predicts Immune Phenotype and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma. Frontiers in oncology 20 34497769
2024 ZC3H13 promotes ITGA6 m6A modification for chronic obstructive pulmonary disease progression. Cellular signalling 17 38670474
2023 ZC3H13 reduced DUOX1-mediated ferroptosis in laryngeal squamous cell carcinoma cells through m6A-dependent modification. Tissue & cell 16 37536262
2023 ZC3H13 Enhances the Malignancy of Cervical Cancer by Regulating m6A Modification of CKAP2. Critical reviews in immunology 14 37943149
2022 circRERE regulates the expression of GBX2 through miR-1299 and ZC3H13/N6-methyladenosine (m6A) to promote growth and invasion of hepatocellular carcinoma cells. Journal of biosciences 14 36222159
2024 Exosome-derived lncRNA A1BG-AS1 attenuates the progression of prostate cancer depending on ZC3H13-mediated m6A modification. Cell division 10 38351022
2025 Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer. Cell biology and toxicology 9 40000487
2025 Methyltransferase ZC3H13 regulates ferroptosis of alveolar macrophages in sepsis-associated acute lung injury via PRDX6/p53/SLC7A11 axis. Functional & integrative genomics 8 40646387
2023 ZC3H13 Accelerates Keloid Formation by Mediating N6-methyladenosine Modification of HIPK2. Biochemical genetics 7 37752292
2025 Identification of m6A methyltransferase-related WTAP and ZC3H13 predicts immune infiltrates in glioblastoma. Scientific reports 6 39910141
2024 hsa_circ_0101050 regulated by ZC3H13 enhances tumorigenesis in papillary thyroid cancer via m6A modification. Heliyon 6 38988519
2024 ZC3H13-Mediated m6A Modification Ameliorates Acute Myocardial Infarction through Preventing Inflammation, Oxidative Stress and Ferroptosis by Targeting lncRNA93358. Inflammation 6 39107569
2024 ZC3H13 knockdown enhances the inhibitory effect of sevoflurane on gastric cancer cell malignancy by regulating the N6-methyladenosine modification of the lncRNA DLX6-AS1. Heliyon 6 39220970
2025 The inhibition of ZC3H13 attenuates G2/M arrest and apoptosis by alleviating NABP1 m6A modification in cisplatin-induced acute kidney injury. Cellular and molecular life sciences : CMLS 5 39985591
2024 ZC3H13 may participate in the ferroptosis process of sepsis-induced cardiomyopathy by regulating the expression of Pnn and Rbm25. Gene 5 39284557
2024 ZC3H13-induced the m6A modification of hsa_circ_0081723 promotes cervical cancer progression via AMPK/p53 pathway. The journal of obstetrics and gynaecology research 5 39476847
2024 ZC3H13 promotes autophagy in bladder cancer through m6A methylation modification of PJA2 and ubiquitination of KSR1. Human cell 4 39614918
2022 Enterovirus 71 VP1 promotes 5-HT release by upregulating the expression of ERICH3 and methyltransferase ZC3H13. Virus research 4 35660571
2025 The role of ZC3H13 in promoting M2 macrophage infiltration via m6A methylation in esophageal squamous cell carcinoma tumor progression. Frontiers in immunology 3 40959082
2024 m6A methyltransferase ZC3H13 improves pulmonary fibrosis in mice through regulating Bax expression. Experimental cell research 3 39307407
2025 ZC3H13 Regulates Ferroptosis to Enhance Osteogenic Differentiation in Osteoporotic BMSCs. Tissue engineering. Part A 2 40130382
2025 M6A methyltransferase ZC3H13-mediated downregulation of GPX4 mRNA stability inhibits the progression of kidney renal clear cell carcinoma (KIRC). Cellular immunology 1 40578066
2025 N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K/Akt/mTOR signaling pathway. Discover oncology 1 40890321
2026 ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. Cancer research 0 41105668
2026 Silencing of Zc3h13 attenuates LPS-induced inflammatory response in macrophages via m6A-dependent stabilization of Spic mRNA. Journal of immunology (Baltimore, Md. : 1950) 0 41847860
2026 Bioinformatics and machine learning identify ITIH4 and ZC3H13 as novel mRNA biomarkers for major depressive disorder that promote microglial M1 polarization. Cytotechnology 0 41890272
2026 ZC3H13-mediated the m6A modification of PAX9 suppresses the progression of reflux esophagitis via improving esophageal epithelial barrier dysfunction. Gene 0 42044732
2026 Epitranscriptomic silencing of the ZC3H13/m6A axis orchestrates immunosuppressive microenvironment remodeling in renal cell carcinoma via CSF2-mediated MDSCs recruitment. Journal of experimental & clinical cancer research : CR 0 42163390
2026 The FOXO3/ZC3H13/SLC3A2 cascade modulates the osteogenic differentiation and ferroptosis of BMSCs. Journal of bioenergetics and biomembranes 0 42217127
2025 ZC3H13 Promotes NSUN4-Mediated Chondrocyte Mitochondrial Dysfunction and Pyroptosis in Temporomandibular Joint Osteoarthritis. Cartilage 0 40433805
2025 ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. Cell death & disease 0 40774945
2025 ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming. Experimental hematology 0 40780498
2025 ZC3H13-induced KLRB1 upregulation relieves the injury of myocardial infarction through N [6]-methyladenosine methylation. Journal of receptor and signal transduction research 0 41175162
2025 PLAU regulated by a m6A writer ZC3H13 plays the oncogenic role in oral squamous cell carcinoma. Cytotechnology 0 41377025

Missed literature

Know a paper Affinage missed for ZC3H13? Flag it for the maintainers and the community.

No submissions yet.